391 related articles for article (PubMed ID: 29225209)
1. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Atheroscler Thromb; 2018 Jun; 25(6):467-476. PubMed ID: 29225209
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Kurinami N; Sugiyama S; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouch K; Jinnouchi T; Jinnouchi H
Diabetes Res Clin Pract; 2018 Aug; 142():254-263. PubMed ID: 29859912
[TBL] [Abstract][Full Text] [Related]
5. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
6. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
8. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
9. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Zhang L; Feng Y; List J; Kasichayanula S; Pfister M
Diabetes Obes Metab; 2010 Jun; 12(6):510-6. PubMed ID: 20518806
[TBL] [Abstract][Full Text] [Related]
11. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y
Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
13. Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus.
Yoshimura Y; Hashimoto Y; Okada H; Takegami M; Nakajima H; Miyoshi T; Yoshimura T; Yamazaki M; Hamaguchi M; Fukui M
J Diabetes Investig; 2023 Oct; 14(10):1175-1182. PubMed ID: 37424302
[TBL] [Abstract][Full Text] [Related]
14. Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Bouchi R; Sonoda N; Itoh J; Ono Y; Fukuda T; Takeuchi T; Kishimoto J; Yamada T; Ogawa Y
Endocr J; 2021 Mar; 68(3):329-343. PubMed ID: 33390421
[TBL] [Abstract][Full Text] [Related]
15. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Phrueksotsai S; Pinyopornpanish K; Euathrongchit J; Leerapun A; Phrommintikul A; Buranapin S; Chattipakorn N; Thongsawat S
J Gastroenterol Hepatol; 2021 Oct; 36(10):2952-2959. PubMed ID: 34129252
[TBL] [Abstract][Full Text] [Related]
16. Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT).
Viswanathan V; Singh KP
Diabetes Technol Ther; 2019 Aug; 21(8):415-422. PubMed ID: 31339784
[No Abstract] [Full Text] [Related]
17. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Shigiyama F; Kumashiro N; Miyagi M; Ikehara K; Kanda E; Uchino H; Hirose T
Cardiovasc Diabetol; 2017 Jul; 16(1):84. PubMed ID: 28683796
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin.
Watanabe Y; Suzuki D; Kuribayashi N; Uchida D; Kato M; Ohashi H; Nagayama D; Yamaguchi T; Ohira M; Saiki A; Tatsuno I
Sci Rep; 2021 May; 11(1):11350. PubMed ID: 34059720
[TBL] [Abstract][Full Text] [Related]
19. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
